Scott Hynes
Overview
Explore the profile of Scott Hynes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zahir H, Murai M, Wu L, Valentine M, Hynes S
J Clin Pharmacol
. 2025 Feb;
PMID: 39920097
Omaveloxolone is approved in the United States and the European Union for the treatment of patients with Friedreich ataxia aged ≥16 years. It is mainly metabolized by cytochrome P450 (CYP)...
2.
Byers L, Navarro A, Schaefer E, Johnson M, Ozguroglu M, Han J, et al.
Clin Lung Cancer
. 2021 May;
22(6):531-540.
PMID: 34034991
Background: This study assessed the checkpoint kinase 1 inhibitor prexasertib in patients with extensive-stage small-cell lung cancer (ED-SCLC). Patients And Methods: This was a parallel-cohort phase II study of 105...
3.
Bendell J, Bischoff H, Hwang J, Reinhardt H, Zander T, Wang X, et al.
Invest New Drugs
. 2019 Nov;
38(4):1145-1155.
PMID: 31707688
Purpose The primary objective was to determine the recommended Phase 2 dose (RP2D) of checkpoint kinase 1 inhibitor, prexasertib, in combination with the p38 mitogen-activated protein kinase inhibitor, ralimetinib, which...
4.
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients
Laquente B, Lopez-Martin J, Richards D, Illerhaus G, Chang D, Kim G, et al.
BMC Cancer
. 2017 Feb;
17(1):137.
PMID: 28202004
Background: The aim of this study was to determine whether checkpoint kinase 1 inihibitor (CHK1), LY2603618, and gemcitabine prolong overall survival (OS) compared to gemcitabine alone in patients with unresectable...
5.
Hong D, Infante J, Janku F, Jones S, Nguyen L, Burris H, et al.
J Clin Oncol
. 2016 Apr;
34(15):1764-71.
PMID: 27044938
Purpose: The primary objective was to determine safety, toxicity, and a recommended phase II dose regimen of LY2606368, an inhibitor of checkpoint kinase 1, as monotherapy. Patients And Methods: This...